FairValu
PFIZER INC

PFIZER INC

PFENYSE

Drug Manufacturers - General • Healthcare

Current Price
$27.960.00%
Market Cap
$159.36B
Shares Outstanding: 5.70B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for PFE

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for PFE

Factor Scorecard

Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.

19/31 signals active· low confidence at 61% coverage
Overall Factor Score
5340-54 band
Growth
240-39 band
Quality
6755-69 band
Valuation
6655-69 band
Financial Health
5340-54 band

Latest results at a glance

Insights from the latest company results and reports · filed 4 Aug 2026

  • Q2 Adjusted EPS Meets Expectations

    Reported adjusted diluted EPS of $0.77 for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $0.68.

  • Revenue Guidance Raised

    Pfizer raised its full-year 2026 revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion.

  • EPS Guidance Reaffirmed

    The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $2.80 to $3.00, which absorbs an impact of approximately $0.10 related to the Innovent Biologics transaction.

  • Operational Revenue Growth

    Focused execution drove 18% year-over-year operational revenue growth from launched and acquired products in the second quarter.

  • No Share Repurchases Planned

    No share repurchases have been completed in 2026, and current financial guidance does not anticipate any repurchases for the remainder of the year.

  • Vaccine Pipeline Milestone

    A pivotal Phase 3 pediatric program for the 25-valent pneumococcal conjugate vaccine candidate PF-07872412 began in May 2026 following positive Phase 2 results.

AI-generated · updated 28 Aug 2026View source filing

Price Chart

NYSE:PFE via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
-0.2%
Declining
Revenue CAGR 3Y
-
Forward Revenue Growth
-0.5%
Declining
Revenue Acceleration
-14.9%
Decelerating

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
0.76
Profitable
EPS Growth
-59.7%
Declining
EPS CAGR 3Y
-
EPS Surprise
12.9%
Strong Beat
Forward EPS
2.98
Profitable
Fwd Revenue Growth
-0.5%
Forward EPS Growth
-2.7%
Declining

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
73.2%
High
Operating Margin
-
Net Margin
6.8%
Positive
ROE
5.1%
Poor
ROIC
-

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$10.98B
Positive
FCF Growth
-11.7%
Declining
FCF Margin
-
Cash Conversion
3.09x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
9.40x
Low
EV / FCFSupporting
20.17x
Typical
Trailing P/ESupporting
36.78x
High
Price / SalesContext
2.50x
Typical

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.27x
Adequate
Quick Ratio
0.41x
Risky
Debt / Equity
0.74x
Moderate
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Net Insider Buys
+1
Buying

Peer Comparison

TickerPrice
PFEPFIZER INC
$27.96
Company Profile

About the Company

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Next Earnings Date

Nov 3, 2026

Loading latest news...